Completed PHASE2 INTERVENTIONAL 2-arm NCT04728321

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

An Open-Label Multi-Center Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 Alone or in Combination With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Sponsor: Akeso

Conditions Hepatocellular Carcinoma

Interventions AK104 AK104 lenvatinib

Updated 5 times since 2021 Last updated: Apr 23, 2024 Started: Jan 27, 2021 Primary completion: Aug 2, 2022 Completion: Aug 2, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatocellular Carcinoma and is currently completed. Akeso leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Nov 2022 — May 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2021 — Nov 2022 [monthly]

Recruiting PHASE2

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso
Akeso Pharmaceuticals, Inc.

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China